Novartis
诺华
elsewhere's corpus does not cover Novartis as a subject — the retrieved material only mentions it in passing as a deal counterparty. What the bundle does show: per a 2023 BlueRun Ventures piece, Novartis partnered with Microsoft to use AI tools for drug discovery, development and commercialization ; and per a July 2025 GaoRong Ventures dispatch, Sironax granted Novartis an exclusive option to acquire its brain-delivery platform . These are isolated transaction references, not a profile of the company itself.
AI-generated — may contain errors, please verify.
Coverage
"Zhongsheng Quanpeptide" Raises Over 300 Million Yuan in Series C Funding to Accelerate Global Expansion of Peptide-Based Innovative Drugs
It has secured multiple international partnerships with MNCs including Novartis and Eli Lilly and Company.
Westlake Valley Intelligent Pharma: Cracking the AAV Delivery Challenge with AI, Entering the Super Track of In Vivo CAR-T — Gene Therapy's Moment in China | Gaorong Future
Chinese gene therapies have a real shot at genuine innovation — even leapfrogging the competition.
Rongbao | Geekplus, Saint Bella Go Public in Hong Kong; Deep Research, Design Agent Launched
See further into the future.
Interview with RayzeBio: Two Funding Rounds in Six Months, How the Surging "Radiopharma" Sector Is Transforming Cancer Treatment | Gaorong Ventures
Accelerating on the "fast track" of TRT therapy.
$1 Billion! BioMap and Sanofi Partner to Develop AI Drug Discovery Models Based on Large Foundation Models | BlueRun Ventures Headlines
The First Commercial Partnership Based on Large Language Models in the Life Sciences Sector
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
Everything Has Two Sides: How Can "Nuclear Radiation" Be Used to Make Anti-Cancer Drugs? | FreeS Report 28
Now is the spring of radiopharmaceuticals.
FreeS Fund Report 16: The Truth About Early-Stage Healthcare Investing and China Speed | Frees Fund
Is early-stage healthcare investment really as "high-cost, high-risk, slow-return" as they say?
China's First AI Microbiome Drug Company "Unknown" Raises Nearly $10 Million in Funding
Leveraging AI and bioengineering technologies to deliver precision management of gut health for Chinese consumers.
